21 December 2020 — AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage […] Scientists are seeing promising early results from the first studies testing gene editing for painful, inherited blood disorders that plague […] The loss of oligodendrocytes (OLs), highly specialized cells of the brain that produce myelin, is a frequent condition in patients […] University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood […] The coronavirus SARS-CoV-2 is known to infect cells via the receptor ACE2. An international research team under German-Finnish coordination has […] THOUSAND OAKS, Calif., Oct. 5, 2020 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating […] A new study conducted by researchers at the University of Eastern Finland found that the PLCG2-P522R genetic variant, which protects […] The immune system’s ability to marshal specialized cells to fight off infection relies in part on tiny molecules called microRNAs, […] Using standard-of-care computed tomography (CT) scans in patients with advanced non-small cell lung cancer (NSCLC), researchers utilized artificial intelligence (AI) […]cell
Tagrisso Approved in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
Gene-editing treatment shows promise for sickle cell disease
Researchers generate a brain cell type crucial to support neural activity
New blood cancer treatment works by selectively interfering with cancer cell signalling
Coronavirus: Study finds further door opener into the cell
Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer
A genetic variant that protects against Alzheimer’s disease promotes immune cell functions
Releasing molecular ‘brake’ kick-starts immune cell function
AI may help predict responses to non-small cell lung cancer systemic therapies